Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
Lipoprotein-associated coagulation inhibitor (LACI) is a plasma-derived protein that inhibits the tissue factor/factor VIIa/calcium/phospholipid complex in a factor Xa-dependent manner. Recombinant LACI (rLACI) added exogenously to plasma prolonged the activated partial thromboplastin time (APTT) and prothrombin time (PT) as a function of rLACI concentration in linear and curvilinear manners, respectively. Under these standard assay conditions, the amounts of rLACI required to double the APTT and PT were approximately 350- and 90-fold the plasma concentration of LACI, respectively. Likewise, addition of antibodies against LACI to pooled normal, factor VIII-deficient, or factor IX-deficient plasma had no effect on their respective APTTs and PTs, demonstrating the insensitivity of these assays to endogenous LACI. The prothrombin time assay was modified by using dilute thromboplastin. Unlike the standard prothrombin time assay, the clotting times were prolonged for factors VIII- or IX-deficient plasma relative to pooled normal plasma in this modified PT assay. Additionally, the degree of factor deficiency, as determined by the APTT assay, was correlated with that determined by the modified PT assay using dilute thromboplastin. When antibodies against LACI were added to pooled normal, factor VIII-deficient, or factor IX-deficient plasma and the prothrombin time assay initiated using dilute thromboplastin, the clotting times for antibody-treated plasma were shorter than for the corresponding plasma in the absence of antibodies. Moreover, the clotting times for factors VIII- and IX-deficient plasmas treated with antibodies raised against LACI were at least as fast as pooled normal plasma in the absence of LACI antibodies when dilute thromboplastin was used to initiate clotting. These results suggest that the prothrombin time assay using dilute thromboplastin may more accurately reflect what occurs in vivo and that LACI may play an important role in the prolonged bleeding of those with hemophilia A or B.
Welsch
D J
DJ
Monsanto Company, St. Louis, MO 63198.
Novotny
W F
WF
Wun
T C
TC
D000911:Antibodies, Monoclonal; D001777:Blood Coagulation / Q000187:drug effects*; D005167:Factor VII / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000494:pharmacology; D006467:Hemophilia A / Q000097:blood*; D006801:Humans; D008074:Lipoproteins / Q000276:immunology / Q000494:pharmacology*; D010314:Partial Thromboplastin Time; D011480:Protease Inhibitors / Q000494:pharmacology*; D011517:Prothrombin Time; D011994:Recombinant Proteins / Q000494:pharmacology; D012016:Reference Values; D013925:Thromboplastin / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000494:pharmacology / Q000502:physiology*
D000911:Antibodies, Monoclonal; D008074:Lipoproteins; D011480:Protease Inhibitors; D011994:Recombinant Proteins; C051928:lipoprotein-associated coagulation inhibitor; D005167:Factor VII; D013925:Thromboplastin